AstraZeneca and Conformetrix form collaboration

Monday, April 16, 2012 10:00 AM

Through a newly-formed research collaboration, Conformetrix, a company focused on optimizing drug discovery and design, will apply its proprietary NMR-based technology across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

Conformetrix will receive an undisclosed upfront payment from AZ, as well as research funding and potential milestones as certain targets are met. The discovery program will be managed by a joint AstraZeneca-Conformetrix research team.

Conformetrix’s NMR-based technology determines accurate three-dimensional structures—or conformations—of drug molecules in their bioactive states. This is achieved without the need for traditional structural information regarding the protein target of each drug and provides researchers with valuable information on how development-stage compounds are likely to interact with their targets. This new information will likely improve AZ’s efficiency and quality of the lead identification, lead optimization and candidate selection stages of drug discovery programs. AZ will also use the technology to determine the bioactive conformations of naturally occurring ligands as templates for drug library enhancement and hit identification.

“We believe [Contormetrix’s] technology will provide a powerful addition to our hit identification and lead optimization approaches, supporting our strategic objectives to improve the quality and choice of candidate compounds for our early pipeline,” said Mike Snowden, vice president and head of discovery sciences, AZ.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs